Phosphodiesterase (PDE) Inhibitors Market Trends

  • Report ID: 2634
  • Published Date: Oct 15, 2024
  • Report Format: PDF, PPT

Phosphodiesterase (PDE) Inhibitors Market Trends

Growth Drivers

Rising Prevalence Of Chronic Disease And Erectile Dysfunction

The phosphodiesterase (PDE) inhibitors market is estimated to witness robust growth on account of the growing concern for the chronic diseases such as heart disease, stroke, diabetes, and prediabetes amongst individuals worldwide, which is raising the need for the treatment of the diseases. Further, increasing expenditure for the treatment of such chronic diseases is also anticipated to drive the growth of the market. According to the World Health Organization, 17.9 million people die each year from cardiovascular disease, an estimated 31% of all death worldwide. Moreover, escalating the prevalence of erectile dysfunction multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia are estimated to support the development of the global market. Furthermore, rapid urbanization and the inherent lifestyle changes, along with high stress at the workplace are rendering young men more susceptible to erectile dysfunction.

Restraints

Potent Drug Interaction of Phosphodiesterase (PDE) inhibitors

The global phosphodiesterase (PDE) inhibitors market is anticipated to hampered by factors such as potential drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and the launch of generics.

Phosphodiesterase (PDE) Inhibitors Market: Key Insights

Base Year

2023

Forecast Year

2024–2036

CAGR

6.1%

Base Year Market Size (2023)

USD 3.15 billion

Forecast Year Market Size (2036)

USD 6.8 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 2634
  • Published Date: Oct 15, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of phosphodiesterase inhibitors is assessed at USD 3.3 billion.

Phosphodiesterase (PDE) Inhibitors Market size was valued at USD 3.15 billion in 2023 and is expected to reach USD 6.8 billion by 2036, registering around 6.1% CAGR during the forecast period i.e., between 2024-2036.

North America industry is likely to hold largest revenue share by 2036, on account of factors such as presence of large pharmaceutical companies and increasing lifestyle changes.

The major players in the market are Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc, AstraZeneca plc, Celgene Corporation, and others.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample